Journal List > Korean J Cytopathol > v.19(2) > 1006515

Korean J Cytopathol. 2008 Sep;19(2):119-125. Korean.
Published online September 30, 2008.  https://doi.org/10.3338/kjc.2008.19.2.119
Copyright © 2008 The Korean Society for Cytopathology
Comparison of Clinical Efficacy between an HPV DNA Chip and a Hybrid-Capture II Assay in a Patient with Abnormal Colposcopic Findings
Tae-Jung Kim, M.D., Chan Kwon Jung, M.D., Ahwon Lee, M.D., Eun Sun Jung, M.D., Young Jin Choi, M.D., Kyo Young Lee, M.D. and Jong Sup Park, M.D.1
Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
1Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Received July 21, 2008; Accepted September 04, 2008.

Abstract

This study was performed to compare the efficacy between a DNA chip method and a Hybrid-Capture II assay (HC-II) for detecting human papillomavirus in patients with intraepithelial lesions of the uterine cervix. From May, 2005, to June, 2006, 192 patients with abnormal colposcopic findings received cervical cytology, HC-II and HPV DNA chip tests, and colposcopic biopsy or conization. We compared the results of HC-II and HPV DNA chip in conjunction with liquid based cervical cytology (LBCC) and confirmed the results of biopsy or conization. The sensitivity of the HPV DNA chip test was higher than HC-II or LBCC. The HPV DNA chip in conjunction with LBCC showed higher sensitivity than any single method and higher sensitivity than HC-II with LBCC. We confirmed that the HPV DNA chip test was more sensitive for detecting HPV in cervical lesions than HC-II, and that it would provide more useful clinical information about HPV type and its multiple infections.

Keywords: HPV; HC-II; HPV DNA chip

Figures


Fig. 1
The comparison of HPV type and histologic results.
Click for larger image

Tables


Table 1
The distribution of HPV genotypes by HPV DNA chip test according to histologic results
Click for larger image


Table 2
Histologic results related to result of cytology and HPV test
Click for larger image


Table 3
Clinical usefulness of cytology and HPV test
Click for larger image


Table 4
Clinical usefulness of HPV test combined with cytology
Click for larger image


Table 5
Comparison between HC-II and DNA chip in cases more than koilocytosis
Click for larger image

References
1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–19.
2. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831–1836.
3. Castle PE, Wacholder S, Sherman ME, et al. Absolute risk of a subsequent abnormal Pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer 2002;95:2145–2151.
4. Rozendaal L, Walboomers JM, van der Linden JC, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996;68:766–769.
5. Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-ontrol study. Lancet 2000;355:2194–2198.
6. Lee MY, Cho CH, Kwon SH, et al. Annual report of gynecologic cancer registry program in Korean for 2002 (Jan. 1st, 2002 - Dec. 31st, 2002). Korean J Obstet Gynecol 2004;47:1029–1070.
7. DeMay RM. Cytopathology of false negatives preceding cervical carcinomas. Am J Obstet Gynecol 1996;175:1110–1113.
8. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities; a systematic review. Ann Intern Med 2000;132:810–819.
9. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:680–686.
10. van Ham MAPC, Melchers WJG, Hanselaar AGJM, Bekkers RLM, Boonstra H, Massuger LFAG. Fluctuations in prevalence of cervical human papillomavirus in women frequently sampled during a single menstrual cycle. Br J Cancer 2002;87:373–376.
11. Quint WGV, Scholte G, van Doorn LJ, Kleter B, Smits PHM, Lindeman J. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF10 PCR and HPV genotyping. J Pathol 2001;194:51–58.
12. Lee JH, Lee KH, Lee IH, et al. Clinical efficacy of HPV DNA chip test in human papillomavirus detection of uterine cervix. Korean J Obstet Gynecol 2006;49:2128–2136.
13. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63–73.
14. Hwang HS, Park M, Lee SY, Kwon KH, Pang MG. Distribution and prevalence of human papillomavirus genotypes in routine pap smear of 2,470 Korean women determined by DNA chip. Cancer Epidemiol Biomarkers Prev 2004;13:2153–2156.
15. An HJ, Cho NH, Lee SY, et al. Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. Cancer 2003;97:1672–1680.
16. Cho NH, An HJ, Jeong JK, et al. Genotyping of 22 human papillomavirus types by DNA chip in Korean women: comparison with cytologic diagnosis. Am J Obstet Gynecol 2003;188:56–62.
17. Kim PY, Lee DW, Seo JH, Sunwoo JG, Bae DH, Jeong DJ. A study for the prevalence of high-risk HPV subtype in uterine cervical neoplasia of Korean women. Korean J Obstet Gynecol 2003;46:2005–2012.
18. Hung CF, Monie A, Alvarez RD, Wu T. DNA vaccines for cervical cancer; from bench to bedside. Exp Mol Med 2007;39:679–689.